TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04268849
Drug: Ferrous sulfate tablets
Normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferrous sulfate tablets containing 60 mg elemental iron
Study: NCT04268849
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
Study: NCT03363464
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dipeptidyl peptidase-4 inhibitor
Study: NCT03451799
Drug: Standard-of-care Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
Study: NCT02312427
Drug: Starting DPP-4 inhibitor after treatment of heart failure
Normalized name: BEEF HEART
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
Study: NCT02312427
Drug: Suspending DPP-4 inhibitor after treatment of heart failure
Normalized name: BEEF HEART
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
Study: NCT04080076
Drug: Oral Tab Tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
Study: NCT00017485
Drug: HPPH
Normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04132375
Drug: INM004
Normalized name: INM004
DrugBank: INM004 (DB17791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Study: NCT00245583
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: minimum does of 50mg/day
Study: NCT00665626
Drug: Fostamatinib disodium (R935788)
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R935788 100 mg tablet, orally, twice-a-day
Study: NCT02949362
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.05mg/kg
Study: NCT00829283
Drug: Sibutramine/Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine 15 mg daily or Orlistat 120mg TID
Study: NCT04573647
Drug: Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
Normalized name: Cenegermin-bkbj 0.002% Ophthalmic Solution [OXERVATE]
DrugBank: Cenegermin (DB13926)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
Study: NCT00667446
Drug: Leuprolide Acetate 3 Month Depot
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00825851
Drug: Transdermal nicotine patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/16h + 10mg/16h to be used 24h
Study: NCT00322153
Drug: memantine ER
Normalized name: memantine Extended Release Oral Capsule
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28mg(7mg capsules) once daily and oral administration for 24 weeks.
Study: NCT02414139
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food.
Study: NCT02133352
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
Study: NCT03143491
Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
Study: NCT03631355
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
Study: NCT04252833
Drug: CT-044
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-044 HCl is a reactive species decomposition accelerant
Study: NCT03986697
Drug: Biktarvy
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
Study: NCT03377361
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03377361
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT03208257
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol hydrochloride infusion
Study: NCT03291418
Drug: ATB-346 OR Placebo
Normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of gastrointestinal effects
Study: NCT03992755
Drug: LIQ861 Inhaled Treprostinil
Normalized name: Treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Study: NCT03476330
Drug: Quercetin (dietary supplement)
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
Study: NCT03402165
Drug: Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
Normalized name: sofosbuvir and ledipasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Response to DAAD's and developing HCC
Study: NCT00349271
Drug: Filgrastime (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastime (G-CSF)
Study: NCT01768247
Drug: HCG (human chorionic gonadotropin)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
Study: NCT03969992
Drug: AeroFact
Normalized name: AeroFact
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized SF-RI 1
Study: NCT03462290
Drug: botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
Study: NCT00378079
Drug: Counseling + Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
Study: NCT02902679
Drug: BMS-986177
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03905447
Drug: PC945
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
Study: NCT02239692
Drug: PICOPREP
DrugBank: Picosulfuric acid (DB09268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
Study: NCT00485368
Drug: Coversyl (perindopril)
Normalized name: Ioversol
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03091777
Drug: GDC-229
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-229 is a vaginal gel.
Study: NCT03091777
Drug: Metronidazole Vaginal Gel 0.75%
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
Study: NCT02232269
Drug: Felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00858234
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
Study: NCT00858234
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
Study: NCT04254263
Drug: pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib 400 mg, orally once daily for one year
Study: NCT00704717
Drug: Rebetol (ribavirin; SCH 18908)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rebetol administered in accordance with approved labeling.
Study: NCT04136756
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered intravenously at specified dose on specified days
Study: NCT04136756
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab administered subcutaneously at specified dose on specified days
Study: NCT02889562
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
Study: NCT02889562
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
Study: NCT03362242
Drug: ARO-AAT Injection
Normalized name: ARO-AAT
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
Study: NCT00003567
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
Study: NCT00003567
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
Study: NCT00003567
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
Study: NCT02220998
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03895762
Drug: Abstral Oral Disintegrating Tablet (ODT)
Normalized name: Abstral
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioid(Fentanyl)
Study: NCT02314143
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules.
Study: NCT02314143
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
Study: NCT04123366
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet
Study: NCT02485938
Drug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogeneic Cardiosphere-Derived Cells (DB15744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Study: NCT04633122
Drug: Ripretinib
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral kinase inhibitor
Study: NCT04633122
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
Study: NCT02306473
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be challenged with inhaled mannitol according to already approved protocols.
Study: NCT01336608
Drug: Fluticasone Furoate/Vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled corticosteroid/long acting beta-agonist
Study: NCT00089674
Drug: AMG 162
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Study: NCT01336608
Drug: Vilanterol
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled long acting beta-agonist
Study: NCT02914145
Drug: Dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration
Study: NCT02763566
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02763566
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02763566
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02763566
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intramuscularly
Study: NCT01933932
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
Study: NCT01933932
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
Study: NCT01933932
Drug: Pegylated G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Study: NCT03984097
Drug: TAK-079
Normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 subcutaneously.
Study: NCT03984097
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide orally.
Study: NCT03984097
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone orally.
Study: NCT03984097
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib subcutaneously.
Study: NCT03984097
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide orally.
Study: NCT03513562
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03513562
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02907710
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT02844621
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg orally once daily
Study: NCT00045604
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00045604
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00045604
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02841540
Drug: H3B-8800 (RVT-2001)
Normalized name: H3B-8800
DrugBank: H3B-8800 (DB14017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3B-8800 (RVT-2001) orally at specified doses and schedules.
Study: NCT01586624
Drug: Vandetanib, Selumetinib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study: NCT01586624
Drug: Vandetanib, Selumetinib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study: NCT04385407
Drug: Sofosbuvir + Simeprevir + Ribavirin
Normalized name: Simeprevir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01586624
Drug: Vandetanib, Selumetinib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.
Study: NCT01586624
Drug: Vandetanib, Selumetinib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment.